恆指午後曾跌逾200點 碧桂園、京東健康及阿里健康挫7%-8%
恆指繼今早曾收復急挫428點或2.3%所有失地倒升3點,半日收僅跌21點後,下午沽盤重現,跌幅曾擴至200點重失18,100關,現報18,203,續跌124點或0.7%,總成交額791億元。
藍籌股普遍下跌;京東健康(06618.HK)中期經調整盈利按年倍增至24.36億人民幣,但股價隨大市回落,午後低見45.8元創逾九個月低,現報46.3元,急吐8.4%。同業阿里健康(00241.HK)午後低見4.63元,現報4.78元,急挫8.4%。
聯想集團(00992.HK)首季少賺66%,午後股價跌幅曾擴至6.1%低見7.43元,創逾兩個月低,現報7.56元,回吐4.4%。京東(09618.HK)中績勝預期,但遭大行降價,該股低見134.1元,現報137元,續跌3.6%。
陷財困碧桂園(02007.HK)扭兩連彈,今天股價再創上市新低,最低見0.76元,現報0.77元,跌7.2%;龍湖(00960.HK)及中海外(00688.HK)也跌3%,報17.18元及16.1元及16.1元。
出口股申洲(02313.HK)、創科(00669.HK)及東方海外(00316.HK)跌逾2%-4%,後者沽壓最大,報118.1元,續跌4.5%。
金融股以中銀(02388.HK)、招行(03968.HK)、國壽(02628.HK)及中國平安(02318.HK)沽壓最大,股價齊跌近3%。績後獲多間大行降價的港交所(00388.HK)最低見287.6元,現報293.6元,續跌2%;匯控(00005.HK)低見58.5元,現報59元,續跌1.6%。友邦(01299.HK)由低位68.35元,掉頭倒升0.7%報70.25元。
百威亞太(01876.HK)、潤啤(00291.HK)及李寧(02331.HK)止跌彈1.5%-3..4%,後兩者跑贏,分別曾高見46.75元及41.45元,現報46.5元及40.75元,反覆回升3%及3.4%。信義光能(00968.HK)由三年低位6.65元,掉頭倒升近2%報7.07元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.